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radiotherapy (3D-CRT) techniques and compared with IMRT 
plans. The 3D-CRT plans were prepared using 3–4 fields and 
IMRT plans consisted of 7–8 fields. The primary objective was 
to treat the planning target volume and to minimize the dose 
to organs at risk (OAR). Volumetric analysis, target coverage 
and conformity of prescribed doses were used in plan 
comparison.  
 
Results: Treatment tolerance was very good in all patients. 
Only 12 patients needed steroids during treatment. 
Adjustment of the dose distribution to the target volume was 
improved and the critical structures were better spared in 
the IMRT plans than in 3D-CRT plans. For all patients the 
mean dose and the maximum dose to OAR were significantly 
reduced in IMRT plans. With respect to target volume, IMRT 
technique reduced the maximum dose while increasing the 
minimum dose, resulting in improved conformity. In same 
patients with tumors located very close to OAR it was 
impossible to give 60Gy for target volume with 3D-CRT 
technique because of not acceptable doses in OAR. 
 
Conclusion: The IMRT technique combined with concurrent 
temozolamide is well tolerated and offers significant 
advantages comparing to 3D-CRT. Application of IMRT allows 
dose reduction at OAR without compromising target 
coverage. 
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Purpose or Objective: There is little consensus about the 
optimal treatment for low-grade glioma (LGG), and the 
clinical management of LGG is one of the most controversial 
areas in neurooncology. Radiation therapy is one option for 
treatment of patients with LGG whereas other options 
include postoperative observation. The aim of the study is to 
report the long-term follow-up of a cohort of adult patients 
with LGG post-operatively irradiated in one institution, and 
to identify prognostic factors for progression free survival. 
 
Material and Methods: Between 1975 and 2005, 180 patients 
with LGG (WHO II) received postoperative irradiation after 
non radical (subtotal or partial) excision. Patients had to be 
18 years of age or older, and have histologic proof of 
supratentorial fibrillary (FA), protoplasmic (PA) or 
gemistocytic astrocytoma (GA). Radiotherapy was given 
within 3 to 10 weeks after surgery. The treatment fields were 
localized and included the preoperative tumor volume, with 
a 1-2 cm margin, treated to a total dose of 50 to 60 Gy in 25 
to 30 fractions over 5 to 6 weeks. 
 
Results: Actuarial ten- year progression free survival ( APFS) 
in the whole group was 19% . The worse prognosis was 
reserved for patients with GA. Ten-year APFS rates for GA, 
PA and FA were 10%, 18% and 22% respectively. 
 
Conclusion: The findings from our long-term cohort of 180 
patients with LGG confirmed by uni- and multivariate analysis 
demonstrated that only astrocytoma histology significantly 
determined the prognosis. The best survival is reserved for 
patients with the fibrillary variant, and the worst for the 
gemistocytic one. 
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Purpose or Objective: To report preliminary results of re-
irradiation with proton therapy (PT) for large-volume 
recurrent high-grade gliomas (rHGG). 
 
Material and Methods: Between January and September 2015 
eight patients (pts) with rHGG (7 glioblastoma - GBM, 1 
anaplastic oligodendroglioma - AOD) were re-irradiated with 
PT. Age at re-irradiation was between 40 and 64 years while 
Karnofsky performance status was 60-100%. Minimum time 
between prior radiotherapy and PT was 8 months. Target 
definition was based on CT, MR, and 18F-DOPA PET imaging. 
GTV included any area of contrast enhancement at MR 
imaging after contrast medium administration plus any 
uptake regions at PET imaging. CTV was generated by adding 
to GTV a 3-mm uniform margin manually corrected in 
proximity of anatomical barriers. CTV was expanded by 4 mm 
to create PTV. PTV volume varied between 55 and 260 cc. 
The patient with AOD received 50.4 GyRBE in 28 fractions (fx) 
while GBM pts 36 GyRBE in 18 fx. Four GBM pts also received 
concomitant temozolomide (75 mg/m2/day, 7 days/week). 
All pts were treated with active beam scanning PT using 2-3 
fields with single field optimization technique.  
 
Results: All pts completed the treatment without breaks. 
Registered acute side effects (according to Common 
Terminology Criteria for Adverse Events versione 4.0) include 
skin erythema with pruritus, alopecia, fatigue, conjunctivitis, 
and headache. All the side effects were grade 1 or 2. There 
were no grade 3 or higher toxicities. One patient developed 
grade 1 neutropenia. Three pts started PT under steroids (2-8 
mg/day); two of them reduced the dose during PT, one kept 
the same steroids dose. None of remaining pts needed 
steroids therapy. During follow-up two pts developed 
radionecrosis (diagnosed at imaging) with mild symptoms 
controlled with steroids. All pts are alive. Four pts have 
stable disease one months after PT, three pts have stable 
disease three months after PT, and one pts progressed five 
months after PT. 
 
Conclusion: PT re-irradiation of large volume rHGG is 
feasible and safe even with concomitant chemotherapy 
administration. Longer follow-up is necessary to assess 
definitive efficacy.  
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Purpose or Objective: We evaluate the tolerance and 
efficiency of robotic hypo fractionated stereotactic 
radiotherapy (hSRT) for patients with Cavernous sinus 
meningiomas in our Institution. 
 
Material and Methods: We retrospectively reviewed patients 
who were treated with robotic hSRT for Cavernous sinus 
meningioma. Multidisciplinary staff approved treatment. A 
dose of 36 Gy was prescribed in 9 fractions. Treatment was 
delivered every other day.  
 
Results: Between 2010 and 2013, 18 evaluable patients with 
a total 18 lesions were treated in our institution with hSRT 
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with median follow up of 18 months (6-40 months). Six 
patients had prior surgical resection of tumor, 12 received 
treatment as first line. The majority (60 %) of lesions were 
close to the optic pathway with median values for GTV 
volume was 9,4 cm3 (0,38-55,66 cm3). The control rates at 
tow years were favorable with stable disease in 100 % 
patients, vision was preserved and improved symptoms in 65% 
patients. We observed no grade 3 or 4 toxicity. The most 
frequent being grade 1 retro-orbital pain (20%). No late 
toxicity was reported and no death during the follow – up 
period.  
 
Conclusion: Robotic Hypo-fractionated stereotactic 
radiotherapy for Cavernous sinus meningioma is feasible and 
provides a satisfactory local control with acceptable 
tolerance, either as a first line treatment or as adjuvant to 
incomplete surgery or relapse. Although this type of tumor 
has a slow evolution, extended follow-up is mandatory.  
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Purpose or Objective: Until the advent of stereotactic 
radiotherapy, the main treatment option consisted of cranial 
radiation for palliation. With a more radical intent, and only 
in selected patients, surgical resection and adjuvant 
radiotherapy was indicated later. The purpose of this study is 
to evaluate the results obtained after treatment with single-
session radiosurgery. 
 
Material and Methods: Between 2002 and 2014, has collected 
a representative sample of 592 patients with histological 
diagnosis of brain metastases, of which 340 were men and 
252 women. The average age in this group was 55.67 years 
(14-82 years) and with a KPS of 90 in 58.3% of patients. The 
most common location of these was lung 51%, followed by 
17.1% mom. The most frequent pathological study 
adenocarcinoma was 23.5%, followed by squamous 10.6%. In 
most 63.2% no surgery was performed. The most common site 
was the frontal 24.4%. All patients were treated with 
radiosurgery (stereotactic radiotherapy) single session with a 
median dose of treatment of 18 Gy. 
 
Results: With a median follow-up of 7 months, median 
survival was 14.23 months in a range of 0-117 months. In 
terms of toxicity, only 3.5% of the presented radiation 
necrosis (21 patients), while the cerebral edema was 
reported in 10.8% (64 patients). 
 
Conclusion: The single session radiosurgery is a conservative 
but with a radical purpose, offering technical and few side 
effects is very convenient for the patient. 
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Purpose or Objective: To access treatment toxity and 
patients’ survival after Volumetric Modulated Arc Therapy, a 
novel rotational Intensity Modulated RadioTherapy (IMRT) 
technique, with Simultaneus in-field Boost (SIB) for patients 
with brain metastases. 
 
Material and Methods: Between November 2010 and March 
2015, 26 patients with 1-3 brain metastases were treated 
with SIB-IMRT in the Department of Radiation Oncology at V. 
Fazzi Hospital (maximum diameter of largest metastasis ≤ 3 
cm, KPS ≥ 70, RPA < III). Mean age was 61 ± 7.5 years. 
Patients were neurologically stable. Extracranial disease 
well-controlled (6-month estimated median life expectancy). 
Patients will undergo contrast-enhanced TC scan of the brain 
for radiotherapy planning purposes. The macroscopic (gross) 
tumor volume (GTV) was drawn on the MRI images. The 
prescription isodose line was generally 3 mm larger than the 
GTV. Patients will be treated with WBRT/SIB using VMAT, 
delivering a total of 30 Gy in 10 fractions to the whole brain 
and SIB doses to brain metastases were 40 Gy to lesions >or= 
2.0 cm and 50 Gy to lesions <2.0 cm in diameter, delivered 
once daily on working days. Following therapy completion, 
patients will be seen every 3 months for the 1st year, then 
every 6 months thereafter. Patients will have MRI brain at 3 
months and 1 year, and every 6 months after the first year. 
Any toxicity was recorded according to the RTOG. 
 
Results: The median follow-up interval was 9 months (range, 
2 months- 16 months). The median overall survival time was 
11 months, and 3 of patients died of disease progression. The 
6-month overall survival was 91%. After SIB-IMRT treatment 
of 42 brain lesions, 35 lesions demonstrated complete 
responses, 5 lesions demonstrated partial responses, 2 lesion 
demonstrated stable disease. Actuarial local tumor control 
rates at 6 months, 1 year and 2 years were 93.9, 82% and 
54%, respectively. Thirty-eight patients did not have any 
adverse events >grade1. The majority of common adverse 
events were grade 2 headaches (4 patients), grade 2 motor 
neuropathy (2 patients), and grade 2 lethargy (2 patient). 
One patient developed a grade 3 headache 5 months after 
receiving SIB-IMRT.  
 
Conclusion: The delivery of 40/50 Gy in 10 fractions to 1 - 3 
BM using VMAT provides a high level of tumor control with 
minimal toxicity. Therefore, we believe there is a need for a 
larger prospective study to establish dosing guidelines for SIB-
IMRT and to pave the way for a randomized trial to compare 
SRS/STS plus WBRT with this approach. 
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Purpose or Objective: To evaluate radiation techniques in 
the treatment of Hodgkin’s Lymphoma (HL) and Non-
Hodgkin’s Lymphoma (NHL) with mediastinal disease over 10-
year period, and the toxicity.  
 
Material and Methods: Between 2003-2015, 173 patients 
(pts) with stage I-III nodal lymphoma were treated in our 
institution: some of these patients were irradiated for HL or 
NHL with mediastinal disease. Some of the patients were 
treated by 3DCRT, others by IMRT 
 
Results: We studied 26 men and 43 women with a median 
age of 26 years. The median follow-up was 43 months. Forty 
nine pts were treated by 3DCRT and 20 pts-by IMRT. The 
median dose received by patients treated for NHL was 40 Gy 
(range: 36-44 Gy) and the median dose received by pts with 
HL was 30 Gy (range: 30-36 Gy). Between 2003-2006, 16 pts 
were treated by 3DCRT vs. 0 by IMRT. Between 2007-2009, 16 
pts received 3DCRT and 1-IMRT. Between 2010-2015, 19 pts 
received IMRT, and no patients 3DCRT. Eleven of the 20 
patients (55%) treated by IMRT and 35/49 pts (71.4%) treated 
by 3DCRT experienced acute toxicity. Among the patients 
treated by 3DCRT, 1 patient experienced grade 1 radiation 
pneumonitis and 2 patients experienced grade 1 acute 
mucositis. No late toxicity was observed in the patients 
treated by IMRT. 
 
Conclusion: Improvement of radiation techniques for HL and 
NHL appears to have improved acute and late clinical safety. 
Longer follow-up is necessary to evaluate very late toxicity. 
 
